Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study

Loehrer, 1992, A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study, J Clin Oncol, 10, 1066, 10.1200/JCO.1992.10.7.1066 Horwich, 2019, EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees, Ann Oncol, 30, 1697, 10.1093/annonc/mdz296 EAU. EAU guidelines on muscle-invasive and metastatic bladder cancer. https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Muscle-invasive-and-Metastatic-Bladder-Cancer-2019.pdf. ESMO. ESMO eUpdate—bladder cancer treatment recommendations. https://www.esmo.org/guidelines/genitourinary-cancers/bladder-cancer/eupdate-bladder-cancer-treatment-recommendations2. von der Maase, 2000, Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study, J Clin Oncol, 18, 3068, 10.1200/JCO.2000.18.17.3068 von der Maase, 2005, Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer, J Clin Oncol, 23, 4602, 10.1200/JCO.2005.07.757 Dash, 2006, Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder, Cancer, 107, 506, 10.1002/cncr.22031 Sonpavde, 2012, Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community, Clin Genitourin Cancer, 10, 1, 10.1016/j.clgc.2011.11.005 De Santis, 2012, Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986, J Clin Oncol, 30, 191, 10.1200/JCO.2011.37.3571 Linardou, 2004, Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: phase II study of the Hellenic Co-operative Oncology Group, Urology, 64, 479, 10.1016/j.urology.2004.04.024 Stensland, 2014, Current approaches to the management of bladder cancer in older patients, Am Soc Clin Oncol Educ Book, 34, e250, 10.14694/EdBook_AM.2014.34.e250 Marschner, 2017, Survival of patients with advanced or metastatic renal cell carcinoma in routine practice differs from that in clinical trials—analyses from the German Clinical RCC Registry, Clin Genitourin Cancer, 15, e209, 10.1016/j.clgc.2016.08.022 Templeton, 2013, Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials, Ann Oncol, 24, 2972, 10.1093/annonc/mdt397 Balar, 2017, First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study, Lancet Oncol, 18, 1483, 10.1016/S1470-2045(17)30616-2 Bamias, 2018, Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC), Ann Oncol, 29, 361, 10.1093/annonc/mdx692 Galsky, 2018, Real-world effectiveness of chemotherapy in elderly patients with metastatic bladder cancer in the United States, Bladder Cancer, 4, 227, 10.3233/BLC-170149 Robinson, 2017, Palliative chemotherapy for bladder cancer: treatment delivery and outcomes in the general population, Clin Genitourin Cancer, 15, e535, 10.1016/j.clgc.2016.12.025 Fisher, 2018, Treatment patterns and outcomes in stage IV bladder cancer in a community oncology setting: 2008–2015, Clin Genitourin Cancer, 16, e1171, 10.1016/j.clgc.2018.07.025 Niegisch, 2018, A real-world data study to evaluate treatment patterns, clinical characteristics and survival outcomes for first- and second-line treatment in locally advanced and metastatic urothelial cancer patients in Germany, J Cancer, 9, 1337, 10.7150/jca.23162 The Danish Bladder Cancer Group. Annual report (in Danish). https://www.sundhed.dk/content/cms/86/15686_dablacadata_-aarsrapport_2017_v2_endelig.pdf. Rosenberg, 2005, Update on chemotherapy for advanced bladder cancer, J Urol, 174, 14, 10.1097/01.ju.0000162039.38023.5f The Danish Bladder Cancer Group. Clinical guidelines (in Danish). http://www.skejby.net/DaBlaCa-web/PIXIapril2020.pdf. Bellmunt, 2012, Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987, J Clin Oncol, 30, 1107, 10.1200/JCO.2011.38.6979 Bellmunt, 2016, Urothelial carcinoma management in elderly or unfit patients, Eur J Cancer Suppl, 14, 1, 10.1016/j.ejcsup.2016.01.001 Siefker-Radtke, 2004, Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience, J Urol, 172, 481, 10.1097/01.ju.0000132413.85866.fc